Intranasal Immunization With an Attenuated pep27 Mutant Provides Protection From Influenza Virus and Secondary Pneumococcal Infections
| Autor: | Jung-ah Choi, Seung Han Seon, Dong-Kwon Rhee, Sukneung Pyo, Manki Song, Eunji Yang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Virulence Factors Secondary infection Orthomyxoviridae medicine.disease_cause Vaccines Attenuated Pneumococcal conjugate vaccine Pneumococcal Infections Pneumococcal Vaccines 03 medical and health sciences Bacterial Proteins Orthomyxoviridae Infections Pandemic medicine Influenza A virus Immunology and Allergy Animals Administration Intranasal Mice Inbred BALB C biology business.industry Body Weight medicine.disease biology.organism_classification Virology Survival Analysis Pneumococcal infections Disease Models Animal 030104 developmental biology Infectious Diseases Treatment Outcome Immunization Pneumococcal vaccine Mutation Female business medicine.drug |
| Zdroj: | The Journal of infectious diseases. 217(4) |
| ISSN: | 1537-6613 |
| Popis: | During influenza pandemics, secondary pneumococcal infections cause excessive mortality. However, the current 13-valent pneumococcal conjugate vaccine, PCV13, provides only limited protection against secondary infection. Therefore, a more effective pneumococcal vaccine is required to protect against secondary pneumococcal infections. Here, intranasal immunization with an attenuated pneumococcal pep27 mutant provides protection from influenza virus infection, and also from secondary pneumococcal challenge. These results indicate that mucosal immunity might be an effective way to reduce the morbidity and mortality due to secondary pneumococcal infections during influenza pandemics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|